"Good publication practice for pharmaceutical companies": Where are we now?

MedGenMed Medscape General Medicine

Volumn 7, Issue 2, 2005, Pages

  Wager, Elizabeth ^a  

^a Sideview   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

ARTICLE; CLINICAL STUDY; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG RESEARCH; EVIDENCE BASED MEDICINE; INTERNET; LAW SUIT; PEER REVIEW; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; PUBLICATION;

EID: 25144508078     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Dyer O. GlaxoSmithKline to set up comprehensive online clinical trials register. BMJ. 2004;329:590.
2. Drug company to make its trial results public. BMJ. 2004;329:366.
3. Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ. 2004;328:1217.
4. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Curr Med Res Opin. 2003;19:149-154. Available at: http://www.gpp-guidelines.org/ Accessed March 23, 2005.
5. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Curr Med Res Opin. 2003;19:147-148.
6. Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990;263:1405-1408.
7. Tramer MR, Reynolds DJM, Moore RA, et al. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997;315:635-640.
8. Melander H, Ahlqvist-Rastad J, Meijer G, Beerman B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171-1173.
9. Wager E. The need for trial identifiers. Curr Med Res Opin. 2003;20:203-206.
10. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet. 2004;364:911-912.
11. Healy DT. Transparency and trust. BMJ. 2004;329:1345.
12. Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004;34:18-23.
13. Sharp D. A ghostly crew. Lancet. 1998;351:1076.
14. Jacobs A, Wager E. European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin. 2005;21:317-321.
15. American Medical Writers Association. Position statement. Available at: http://www.amwa.org Accessed December 21, 2004.
16. Wager E. Drug industry is increasingly allowing employees to be named as authors. BMJ. 1996;312:1423.
17. Merck. Corporate responsibility: policies and performance: social. Ethical clinical trials. Available at: http://www.merck.com/about/cr/policies_performance/social/ clinical_trials.html Accessed March 18, 2005.
18. PhRMA. Principles on conduct of clinical trials and communication of clinical trial results. 2003. Available at: http://www.phrma.org/publications/publications//2004-06-30.1035.pdf Accessed December 20, 2004.
19. Begg C, Cho M, Eastwood S, et al. Improving the quality and reporting of randomized controlled trials. JAMA. 1996;276:637-639.